Physician profile
Howard Antosofsky
NPI 1013927235
$5,072.24
in general payments reported to CMS, 2019-2025
44 companies · $783 in 2025
The $783 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $794 · 2020: $619 · 2021: $539 · 2022: $776 · 2023: $749 · 2024: $812 · 2025: $783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,344.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $605.10 | 2019-2022 | |
| Abbvie INC. | $563.03 | 2019-2025 | Linzess, Ubrelvy, Viberzi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $514.89 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $379.64 | 2019-2024 | Dificid |
| Lilly USA, LLC | $300.99 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $283.73 | 2019-2025 | Breztri |
| Exact Sciences Corporation | $210.14 | 2023-2024 | Cologuard Collection Kit |
| Intercept Pharmaceuticals, INC. | $198.90 | 2019-2025 | |
| Novo Nordisk INC | $166.78 | 2019-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $166.52 | 2022-2024 | Nucala |
| Daiichi Sankyo INC. | $153.04 | 2020-2022 | |
| Amgen INC. | $149.45 | 2019-2025 | Tavneos |
| Endo Pharmaceuticals INC. | $139.34 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $126.63 | 2023 | Zeposia |
| Pfizer INC. | $99.67 | 2019-2023 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Antosofsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.